Squamous Cell Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Advanced Squamous Cell Lung Cancer
Conditions: Advanced Lung Squamous Cell Carcinoma Interventions: Radiation: low-dose radiation therapy and stereotactic body radiation therapy; Drug: chemotherapy; Drug: Sintilimab Sponsors: Sichuan University; Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab vs. Sintilimab + Chemotherapy in Advanced Squamous Cell Lung Cancer
Conditions: Advanced Lung Squamous Cell Carcinoma Interventions: Radiation: low-dose radiation therapy and stereotactic body radiation therapy; Drug: chemotherapy; Drug: Sintilimab Sponsors: Sichuan University; Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: Tirelizumab; Drug: Nab paclitaxel; Drug: Carboplatin; Radiation: Radiotherapy Sponsors: Ruijin Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials

Prospective Assessment of HPV Associated Anogenital Pathology in Female Patients and Female Partners of Patients With Confirmed HPV Associated Oropharyngeal Carcinoma, PAP-OP Study
Conditions: Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Squamous Cell Carcinoma; Stage IV Pancreatic Cancer AJCC v8 Interventions: Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Magnetic Resonance Imaging; Procedure: Computed Tomography; Procedure: Biospecimen Collection Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials

Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
Conditions: Squamous Cell Carcinoma of the Oropharynx; Squamous Cell Carcinoma, Unknown Primary Interventions: Device: Versius Surgical System Sponsors: CMR Surgical Ltd; Liverpool University Hospitals NHS Foundation Trust; Sintesi Research S.r.l. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
Conditions: Head and Neck Cancer; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck Interventions: Drug: Xevinapant; Drug: Carboplatin; Drug: Paclitaxel; Radiation: Radiation Therapy Sponsors: University of Chicago; EMD Serono Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas
Conditions: Esophageal Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma Interventions: Drug: Camrelizumab; Drug: Dalpiciclib 100mg; Drug: Dalpiciclib 150mg Sponsors: West China Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
Conditions: Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable Interventions: Drug: Cetuximab; Drug: Zimberelimab; Drug: Docetaxel; Drug: Cisplatin Sponsors: Xuekui Liu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials

Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Sponsors: Hebei Medical University Fourth Hospital; Handan Central Hospital; Xingtai People ' s Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Conditions: Metastatic Penile Squamous Cell Carcinoma; Stage III Penile Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Unresectable Penile Squamous Cell Carcinoma Interventions: Drug: Enfortumab Vedotin Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) Interventions: Drug: Netopitam Palonosetron capsules and dexamethasone Sponsors: Sichuan Cancer Hospital and Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy; Pembrolizumab Interventions: Drug: Pembrolizumab; Drug: Cisplatin; Drug: Carboplatin; Drug: Nedaplatin; Drug: Nab paclitaxel; Drug: Docetaxel; Drug: Liposomal paclitaxel; Drug: Fluorouracil Sponsors: Beijing Tongren Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: Cisplatin; Drug: Paclitaxel-albumin Sponsors: Beijing Tongren Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated LA HNSCC: a Multi Cohort, Prospective Phase II Study
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: Cisplatin; Drug: Paclitaxel-albumin Sponsors: Beijing Tongren Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials